Wolverine Asset Management LLC Buys New Holdings in Denali Therapeutics (NASDAQ:DNLI)

Wolverine Asset Management LLC acquired a new stake in Denali Therapeutics (NASDAQ:DNLI) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 15,966 shares of the company’s stock, valued at approximately $249,000.

A number of other large investors have also recently modified their holdings of DNLI. Gilder Gagnon Howe & Co. LLC acquired a new stake in Denali Therapeutics in the fourth quarter valued at approximately $237,000. NF Trinity Capital Hong Kong Ltd purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at approximately $1,564,000. Wells Fargo & Company MN purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at approximately $621,000. Artal Group S.A. purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at approximately $7,820,000. Finally, Allianz Asset Management GmbH purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at approximately $3,121,000. 60.98% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Several equities analysts have recently commented on the company. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research note on Tuesday, April 3rd. Evercore ISI began coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $23.00 target price for the company. Goldman Sachs began coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating on the stock. Morgan Stanley began coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 target price on the stock. Finally, JPMorgan Chase began coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Denali Therapeutics currently has an average rating of “Buy” and a consensus price target of $23.25.

Shares of DNLI traded down $0.78 during trading hours on Friday, reaching $18.11. 152,689 shares of the company’s stock traded hands, compared to its average volume of 371,931. The firm has a market capitalization of $1,710.11 and a price-to-earnings ratio of -3.07. Denali Therapeutics has a twelve month low of $14.72 and a twelve month high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Monday, March 19th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.47). research analysts expect that Denali Therapeutics will post -0.56 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/15966-shares-in-denali-therapeutics-inc-dnli-purchased-by-wolverine-asset-management-llc.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease.

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply